Aigen Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

Aigen Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-6,335	Closed	-$298K	–	778
2024 Q3	$298K	Buy	+6,335	New	+$321K	0.06%	474
2024 Q2	–	Sell	-6,656	Closed	-$454K	–	825
2024 Q1	$454K	Buy	+6,656	New	+$476K	0.1%	305
2022 Q1	–	Sell	-6,916	Closed	-$488K	–	651
2021 Q4	$488K	Buy	6,916 +4,044	+141%	+$353K	0.03%	631
2021 Q3	$321K	Sell	2,872 -34,204	-92%	-$4.3M	0.06%	328
2021 Q2	$6M	Sell	37,076 -16,859	-31%	-$2.05M	1.05%	18
2021 Q1	$6.57M	Buy	53,935 +33,737	+167%	+$5.09M	0.87%	19
2020 Q4	$3.09M	Buy	+20,198	New	+$2.39M	0.4%	51

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aigen Investment Management's CRSP Position: Q4 2024 in Review

Aigen Investment Management sold out of CRISPR Therapeutics (CRSP) in Q4 2024, closing a stake of 6,335 shares — an estimated $298K sold.

Aigen Investment Management first reported a position in CRSP in Q4 2020 and held it in 7 quarters. The position peaked at $6.57M in Q1 2021. 404 funds tracked by Wall St. Rank hold CRSP as of Q4 2024.

Aigen Investment Management reported no remaining CRISPR Therapeutics position as of Q4 2024 after selling out during the quarter.
Aigen Investment Management sold 6,335 CRISPR Therapeutics shares in Q4 2024, an estimated $298K.
Aigen Investment Management first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 7 quarters.
Aigen Investment Management's CRISPR Therapeutics position peaked at $6.57M in Q1 2021.
404 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2024.

Based on Aigen Investment Management's 13F filing for Q4 2024, filed 6 Feb 2025.